GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NaviFUS Corp (ROCO:6872) » Definitions » Total Liabilities

NaviFUS (ROCO:6872) Total Liabilities : NT$54.04 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NaviFUS Total Liabilities?

NaviFUS's Total Liabilities for the quarter that ended in Dec. 2024 was NT$54.04 Mil.

NaviFUS's quarterly Total Liabilities declined from Jun. 2024 (NT$69.68 Mil) to Sep. 2024 (NT$63.75 Mil) and declined from Sep. 2024 (NT$63.75 Mil) to Dec. 2024 (NT$54.04 Mil).

NaviFUS's annual Total Liabilities increased from Dec. 2022 (NT$21.19 Mil) to Dec. 2023 (NT$53.40 Mil) and increased from Dec. 2023 (NT$53.40 Mil) to Dec. 2024 (NT$54.04 Mil).


NaviFUS Total Liabilities Historical Data

The historical data trend for NaviFUS's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NaviFUS Total Liabilities Chart

NaviFUS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial 6.76 25.88 21.19 53.40 54.04

NaviFUS Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.40 68.89 69.68 63.75 54.04

NaviFUS Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

NaviFUS's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=33.564+(20.174+0.3
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=54.04

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=546.687-492.649
=54.04

NaviFUS's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=33.564+(20.174+0.3
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=54.04

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=546.687-492.649
=54.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NaviFUS Total Liabilities Related Terms

Thank you for viewing the detailed overview of NaviFUS's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


NaviFUS Business Description

Traded in Other Exchanges
N/A
Address
No. 508, Section 7 , Zhongxiao East Road, 16th Floor, Nangang District, Taipei City, TWN, 103
NaviFUS Corp is a Biotech company providing novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery. Its product, the NaviFUS System, is designed to utilize non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision for treatment outcomes. Its vision is to cater to CNS disease patients locally and globally by bringing therapeutic ultrasound technology to clinical use.

NaviFUS Headlines

No Headlines